Subscribe to Newsletter
Testing & Processing Cannabinoid analysis, Potency testing, Medical research, Psychedelics, Business, Profession

The Latest in Cannabis Science

Every month, we carefully curate the top stories from across the fields of medical research, testing, processing, and plant science. We also bring you the latest in the world of cannabis business and legislation. Want it all in your inbox? Sign up here.

Subscribed already? Good. Not quite sold? Keep reading.

What’s Going On?

Research and Medicine

Genomic study with over one million participants sheds light on the underlying disease biology and public health implications of cannabis use disorder and its links to multiple health problems, such as psychiatric disorders and lung cancer. Link

Washington State University-led analysis reveals that more than 80 percent of participants no longer use over the counter and prescription sleep aids when using THC products. Link

Meta-analysis of 57 prior studies reveals cannabis exposure in pregnancy is found to be associated with adverse birth outcomes, including cognitive and behavioral effects. Link

Testing + Processing

Creation of evidence-based interactive mapping tool allows for regulation of THC concentration in cannabis products. Link

Business + Regulation

US states with medical cannabis access see decline in non-medical prescription opioid use. Link

US marijuana operator MariMed loses $646,000 in fraudulent recipient scam. Link

And Finally…

Cannabis of the future

As we plan ahead to the new year with fresh and exciting discoveries awaiting us, a recent article about cannabinoid production caught my eye. After years of research, scientists are now producing THC, CBD, and other cannabinoids in bioreactors using yeast. No plants required. The touted upside? An improved environmental footprint for one.

But the efforts were not met with universal positivity. A conversation chain on X/Twitter highlighted how unsure some people feel about the future impact of the new manufacturing approach. Gary Bastoky said, “[...] it will be super expensive and controlled by Big Pharma and the medical community. This is presented as if it were a good thing, it’s not.” 

Jon Storz was also evidently not keen on non-plant synthesis: “Completely counter to the entire point in lobbying for legalization. Stay away from manufactured garbage.”

Receive content, products, events as well as relevant industry updates from The Cannabis Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Jessica Allerton

Associate Editor, The Analytical Scientist

Register to The Cannabis Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Cannabis Scientist magazine